MPOX
JOIN

Inactivated viral vaccine against Chikungunya virus: standardized template with key considerations for a benefit/risk assessment

This paper uses the BRAVATO inactivated virus vaccine template to review the features of an inactivated whole chikungunya virus (CHIKV) vaccine that has been evaluated in several preclinical studies and clinical trials.

Access the publication here >

More SAFETY TEMPLATES

Standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever

June 2, 2025

Comirnaty COVID-19 mRNA vaccine: standardized template with key considerations for a benefit-risk assessment

August 27, 2024

Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses

October 26, 2023

Live-attenuated viral vaccines: standardized template for collection of key information for benefit-risk assessment

October 13, 2023

Viral vector vaccines: standardized template for collection of key information for benefit-risk assessment

October 13, 2023

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

October 13, 2023
View All

More Safety Templates

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

Linkedin

© Brighton Collaboration  2023. All rights reserved.